PMC:7321036 / 47326-48392
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T379 | 120-125 | Body_part | denotes | Cells | http://purl.org/sig/ont/fma/fma68646 |
| T380 | 246-254 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T381 | 279-283 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T382 | 761-768 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T383 | 824-844 | Body_part | denotes | extracellular matrix | http://purl.org/sig/ont/fma/fma9672 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T235 | 181-189 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T236 | 192-201 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T237 | 203-207 | Disease | denotes | STAR | http://purl.obolibrary.org/obo/MONDO_0010408 |
| T238 | 263-271 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T239 | 321-330 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T240 | 850-859 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T241 | 941-949 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T242 | 1057-1065 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T601 | 53-62 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signaling |
| T602 | 120-125 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | Cells |
| T603 | 222-227 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T604 | 243-245 | http://purl.obolibrary.org/obo/CLO_0008192 | denotes | NP |
| T605 | 279-283 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T606 | 310-312 | http://purl.obolibrary.org/obo/CLO_0001382 | denotes | 48 |
| T607 | 335-336 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T608 | 389-395 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
| T609 | 434-442 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T610 | 609-617 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T611 | 650-652 | http://purl.obolibrary.org/obo/CLO_0008933 | denotes | S5 |
| T612 | 793-794 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T613 | 884-893 | http://purl.obolibrary.org/obo/SO_0000418 | denotes | signaling |
| T614 | 1014-1019 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T615 | 1020-1030 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing as |
| T616 | 1031-1032 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T334 | 25-35 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T335 | 100-109 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T336 | 148-157 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T337 | 158-167 | Chemical | denotes | molecules | http://purl.obolibrary.org/obo/CHEBI_25367 |
| T338 | 243-245 | Chemical | denotes | NP | http://purl.obolibrary.org/obo/CHEBI_50803|http://purl.obolibrary.org/obo/CHEBI_53793|http://purl.obolibrary.org/obo/CHEBI_73425 |
| T341 | 374-384 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T342 | 424-433 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T343 | 544-553 | Chemical | denotes | inhibitor | http://purl.obolibrary.org/obo/CHEBI_35222 |
| T344 | 599-608 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T345 | 650-652 | Chemical | denotes | S5 | http://purl.obolibrary.org/obo/CHEBI_29386 |
| T346 | 761-768 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T347 | 875-877 | Chemical | denotes | S3 | http://purl.obolibrary.org/obo/CHEBI_29388 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T332 | 44-62 | http://purl.obolibrary.org/obo/GO_0051403 | denotes | p38 MAPK signaling |
| T333 | 48-62 | http://purl.obolibrary.org/obo/GO_0000165 | denotes | MAPK signaling |
| T334 | 48-52 | http://purl.obolibrary.org/obo/GO_0004707 | denotes | MAPK |
| T335 | 53-62 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
| T336 | 741-753 | http://purl.obolibrary.org/obo/GO_0051179 | denotes | localization |
| T337 | 884-893 | http://purl.obolibrary.org/obo/GO_0023052 | denotes | signaling |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1027 | 44-52 | Gene | denotes | p38 MAPK | Gene:26416 |
| 1028 | 77-81 | Gene | denotes | CDKs | |
| 1029 | 557-564 | Gene | denotes | CSNK2A1 | Gene:1457 |
| 1030 | 569-576 | Gene | denotes | CSNK2A2 | Gene:1459 |
| 1031 | 759-760 | Gene | denotes | N | Gene:43740575 |
| 1032 | 263-273 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1033 | 941-951 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 1034 | 1014-1019 | Species | denotes | human | Tax:9606 |
| 1035 | 374-384 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 1036 | 526-539 | Chemical | denotes | Silmitasertib | |
| 1037 | 966-979 | Chemical | denotes | silmitasertib | |
| 1038 | 181-201 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
| 1039 | 321-330 | Disease | denotes | infection | MESH:D007239 |
| 1040 | 850-859 | Disease | denotes | infection | MESH:D007239 |
| 1041 | 1057-1065 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T317 | 0-119 | Sentence | denotes | We found pharmacological inhibitors of CK2, p38 MAPK signaling, PIKFYVE, and CDKs to possess strong antiviral efficacy. |
| T318 | 120-331 | Sentence | denotes | Cells were pre-treated with inhibitor molecules, followed by SARS-CoV-2 infection (STAR Methods), and virus quantity (anti-NP antibody against SARS-CoV-2) and cell viability were quantified 48 h after infection. |
| T319 | 332-525 | Sentence | denotes | As a positive control and for comparison, remdesivir was tested, and the expected favorable antiviral activity was observed (half maximal inhibitory concentration [IC50 ] = 1.28 μM; Figure 7B). |
| T320 | 526-654 | Sentence | denotes | Silmitasertib, an inhibitor of CSNK2A1 and CSNK2A2, was found to possess antiviral activity (IC50 = 2.34 μM; Figures 7C and S5). |
| T321 | 655-952 | Sentence | denotes | In conjunction with data supporting physical interaction (Gordon et al., 2020) and co-localization with N protein (Figure 5F), as well as a potential role in remodeling extracellular matrix upon infection (Figures 5 and S3), CK2 signaling appears to be an important pathway hijacked by SARS-CoV-2. |
| T322 | 953-1066 | Sentence | denotes | Furthermore, silmitasertib is currently being considered for human testing as a potential treatment for COVID-19. |